ClinicalTrials.gg
RecruitingNCT05211401RITA-MI2Updated Nov 10, 2026

Rituximab in Patients With ST-elevation Myocardial Infarction

A Phase 2 interventional study of Active arm 1000 mg and Placebo arm in ST Elevated Myocardial Infarction, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.
Updated Nov 10, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
372
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in ST Elevation Myocardial Infarction with a site in France — 7 open to participants now, 11 under way, 5 of them phase 3. ST Elevation Myocardial Infarction · France.

Planned enrollment
19th of 40
372 · median 325
Started
2022
with 2 others
Phase 2
2 of 49
1 open now
Primary completion
2027-11
later than 7 of 10 live
Registered
41st of 49
by date
Lead sponsor
9 of 49
Assistance Publique - Hôpitaux de Paris

Among the 49 studies in ST Elevation Myocardial Infarction with a site in France, this one is the 19th largest by planned enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2022, is one of 2 in phase 2, reaches primary completion later than 7 of the 10 other live ones, and was the 41st registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

7 of the 49 studies in ST Elevation Myocardial Infarction with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in ST Elevation Myocardial Infarction with a site in France, or all of them as a file.
02

Study summary

The main objective is to compare the effect of a single injection of two doses of rituximab versus placebo on 6 months left ventricular systolic function, using CMR, in patients who have had an acute anterior STEMI. Following the sponsor's decision to stop enrolment in the 200 mg arm, the primary objective of the study is to evaluate the efficacy of a single 1000 mg dose of rituximab versus placebo.

The primary endpoint is the left ventricular ejection fraction (LVEF) by CMR at 6 months.

Read the detailed description

RITA-MI 2 is an european phase IIb, multi-center, randomized, parallel, double-blind, placebo-controlled, clinical trial to assess the impact of B cell depletion with the CD20 mAb rituximab (1000mg) on left ventricular dysfunction and cardiac remodelling after acute MI.

Sample size :

372 patients, 1:1 ratio

Assessement:

Patients will be recruited immediately after admission for MI. The aim is to start the infusion of IMP within 3 hours of PPCI (defined as first balloon inflation).

Eligible patients will be offered to enter the study. In France, Spain and Czech Republic: If they accept, the investigator will collect informed written consent from the patient or from a person of trust/next of kin if the patient is unable to consent. While In Germany, UK and Netherlands, only the patient will be informed and will be able to give consent and no next-of-kin will be informed and have the possibility to give consent.

Once the inclusion is confirmed, a specific study blood sample will be taken for later assessment of cytokines and biomarkers related to immune responses, inflammation and cardiac remodelling. It will also be done at discharge and at 6 months.

According to usual practice the following blood exams will be done: Kidney function parameters (including serum creatinine, BUN, electrolytes, calcium and eGFR). It will also be done at day 5 (+ 2 days) and at 6 months.

NT-pro-BNP will be performed at admission and at 6 months. Blood leukocytes, platelets and hematologic/haemostatic parameters will also be measured at admission and at 6 months.

The randomization will be performed and the pharmacy will extemporaneously prepare (aseptically) 2 infusion bags per patient (cf. treatments below).

During the infusion, the patient will be carefully monitored with continuous cardiac telemetry:

  • 12 lead ECG with QTc measurement will be performed pre-dosing and post-dosing at admission, discharge and at 6 months.
  • Kidney functions. The patients will be carefully monitored by their treating physicians, as done in usual care, with a special attention to the occurrence of any adverse event related to treatment.

CMR will be done at 5 days (+ 2 days) to assess the left ventricular (LV) function, the infarct size and microvascular obstruction and at 6 months.

Study staff at the clinical sites will contact each patient at 30 days, 3 months and 12 months following randomization, by phone or during a hospital visit.

The patient participation will last after the 12-month visit.

03

Conditions studied

  • ST Elevated Myocardial Infarction

Keywords

  • Acute Myocardial Infarction
  • Anterior STEMI
  • Rituximab
  • Left ventricular systolic function
  • CMR
  • Cardiac remodelling
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Age ≥ 18 years with no upper limit (women must be either defined as being amenorrhoeic for greater than 2 years with an appropriate clinical profile, e.g. age appropriate (>55 years old), history of vasomotor symptoms) or having documented hysterectomy and/or bilateral oophorectomy) ;
  • Clinical evidence at presentation of anterior ST-elevation myocardial infarction (STEMI) ) involving the proximal or mid left anterior descending (LAD) defined as symptoms suggestive of acute myocardial ischemia, an showing ST-segment elevation ≥2 mm in ≥2 contiguous leads in V1 to V4 or a large inferior MI (right coronary artery (RCA), or left circumflex (LCx) coronary artery) with evidence of low- (LVEF\<45%);
  • Complete occlusion (i.e. TIMI flow 0-1) of proximal or mid left anterior descending (LAD) right coronary artery (RCA), or left circumflex (LCx) coronary artery on urgent angiography interpreted as the infarct-related artery (IRA);
  • Onset of worse symptoms within 48 hours before primary PCI;
  • Patients with neutrophils >1.5 x 109/L at the moment of admission
  • Patients with counts >75 x 109 /L at the moment of admission
  • Plan to provide primary percutaneous angioplasty (PPCI) for the patient within 2 hours of ECG diagnosis; confirmed before enrollment;
  • Ability to start infusion of rituximab within 3 hours of PPCI ; confirmed before enrollment;
  • Written .

Exclusion Criteria:

Exclusion Criteria :

  • History of previous MI without documented preserved left ventricular ejection fraction (LVEF >50%) prior to the current admission will be an exclusion criterion;
  • Presentation with cardiac arrest;
  • Cardiogenic shock (defined as systolic blood pressure \<90 mmHg for >30minutes, or necessitating vasopressors to achieve a blood pressure ≥90 mmHg);
  • Cardiac electrical instability (defined as complete heart block needing temporary pacing or any tachyarrhythmia needing cardioversion);
  • Patients with Killip class III heart failure;
  • History of severe chronic renal failure (define as stage 4 ( = 15-29 mL/min) or worse);
  • History of , or tuberculosis;
  • Patient positive for point of care bedside test of Ag HBs;
  • Severe, progressive infections documented;
  • Active COVID-19 infection or COVID-19 infection within 3 months;
  • Patient with documented severe immune deficiency;
  • Presence, or history in ≤ five years, of an ongoing cancer, (except in situ cancer of the cervix or basal cell carcinoma);
  • > 450 msecs in males, > 470msecs in females;
  • Any oral or intravenous treatment, immune modulatory monoclonal antibodies or immunodepleting therapy at any time (inhalers and topical creams with are permitted);
  • Previous history of major organ transplant including renal transplant;
  • Known to the active substance of rituximab or to proteins of murine origin, or to any of the other ;
  • Any to any of the rituximab premedication drugs;
  • Contraindications to injectable Polaramine:

Risk of closed-angle glaucoma, Risk of urinary retention linked to urethro-prostatic disorders;

  • Expected need for vaccination with a during the study, including incomplete vaccination courses (in case, life, attenuated vaccine must be administered at least 30 days before inclusion in study);
  • Absence of a complete COVID-19 vaccination scheme (including recovery from documented COVID infection) as approved at the time of enrollment in the country where the patient is recruited;
  • Any obvious contraindications for MRI or conditions which will impede image acquisition for example:

Severe claustrophobia

Non-MRI compatible permanent pacemaker

Patients who have a metallic foreign body (metal silver) in their eye, or who have an aneurysm clip in their brain

Patients who have had metallic devices placed in their back

Known hypersensitivity to imaging products (gadoteric acid, meglumin or any drug containing gadolinium)

  • Known hepatic failure;
  • Previous history of progressive multifocal leukoencephalopathy;
  • Inclusion in other interventional drug study within the previous 3 months;
  • Inability to comply with study procedures;
  • Patients under guardianship or curatorship.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
372 participants (estimated)

Study arms

  • Experimental
    Active arm 1000 mg

    Active arm 1000 mg: 1 bag containing 1000 mg of rituximab\* in 500 ml of NaCl 0.9% \* Mabthera® and all registered biosimilars are likely to be used in this trial.

    Drug: Active arm 1000 mg

  • Placebo comparator
    Placebo arm

    1 bag of 500 ml of NaCl 0.9%

    Drug: Placebo arm

Interventions

  • DrugActive arm 1000 mg

    Active arm 1000 mg: 1 bag containing 1000 mg of rituximab\* in 500 ml of NaCl 0.9% \* Mabthera® and all registered biosimilars are likely to be used in this trial

  • DrugPlacebo arm

    Placebo arm: 1 bag of 500 ml of NaCl 0.9%

06

What researchers measure

Primary outcomes

  1. Left ventricular ejection fraction (LVEF) by CMR at 6 months.

    To compare the effect of a single injection of two doses of rituximab versus placebo on 6 months left ventricular systolic function, using CMR, in patients who have had an acute anterior STEMI.

    Time frame: 6 months

Secondary outcomes

  1. Infarct size by CMR

    To compare the effects of rituximab versus placebo on infarct size by CMR at day 5 (+/-2) and at 6 months.

    Time frame: At day 5 (+/-2) and at 6 months

  2. Oedema extension by CMR

    To compare the effects of rituximab versus placebo on oedema extension by CMR at day 5 (+/-2) .

    Time frame: At day 5 (+/-2)

  3. T2 relaxation time at ischemic region by CMR

    To compare the effects of rituximab versus placebo on T2 relaxation time at ischemic region by CMR (using T2 mapping) at day 5 (+/-2).

    Time frame: At day 5 (+/-2)

  4. Microvascular obstruction by CMR

    To compare the effects of rituximab versus placebo on microvascular obstruction by CMR (hypointense areas within LGE) at day 5 (+2/-) .

    Time frame: At day 5 (+/-2)

  5. NT-pro-BNP

    To compare the effects of rituximab versus placebo on NT-pro-BNP at 6 months.

    Time frame: At 6 months

  6. Adverse event related to treatment

    To compare the effects of rituximab versus placebo on any adverse event related to treatment .

    Time frame: Until 12 months

07

Study locations

1 of 1 sites recruiting
  • Cardiology department, Hôpital Bichat, AP-HP
    Paris, 75018, France
    Recruiting
08

References and documents

Publications

  • Yerly A, van der Vorst EPC, Schindewolf M, Kotelis D, Noels H, Doring Y. Chemokine-receptor-guided B-cell immunity in cardiovascular disease. Basic Res Cardiol. 2025 Dec;120(6):1075-1090. doi: 10.1007/s00395-025-01140-x. Epub 2025 Sep 23. PubMed 40986007 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Nov 2027, 65 months after the start.

Of 31 phase 2 interventional studies under ST Elevation Myocardial Infarction, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's planned 65 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2022
First posted
Jan 27, 2022
StartActual
Jun 1, 2022
Primary completionEst.
Nov 2027
CompletionEst.
May 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 criteria edited
What changed in the criteria
  • Edited- Clinical evidence at presentation of anterior ST-elevation myocardial infarction (STEMI) ) involving the proximal or mid left anterior descending (LAD) defined as symptoms suggestive of acute myocardial ischemia, an electrocardiogram showing ST-segment elevation ≥2 mm in ≥2 contiguous leads in V1 to V4 or a large inferior MI (right coronary artery (RCA), or left circumflex (LCx) coronary artery) with evidence of low-ejection fraction (LVEF<45%);
  • EditedComplete occlusion (i.e. TIMI flow 0-1) of proximal or mid left anterior descending (LAD) right coronary artery (RCA), or left circumflex (LCx) coronary artery on urgent angiography interpreted as the infarct-related artery (IRA);
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Eligibility 2 criteria edited
    What changed in the criteria
    • Edited- Clinical evidence at presentation of anterior ST-elevation myocardial infarction (STEMI) ) involving the proximal or mid left anterior descending (LAD) defined as symptoms suggestive of acute myocardial ischemia, an electrocardiogram showing ST-segment elevation ≥2 mm in ≥2 contiguous leads in V1 to V4 or a large inferior MI (right coronary artery (RCA), or left circumflex (LCx) coronary artery) with evidence of low-ejection fraction (LVEF<45%);
    • EditedComplete occlusion (i.e. TIMI flow 0-1) of proximal or mid left anterior descending (LAD) right coronary artery (RCA), or left circumflex (LCx) coronary artery on urgent angiography interpreted as the infarct-related artery (IRA);
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05211401
Responsible party
Sponsor
First posted
Jan 27, 2022
Start date
Jun 1, 2022
Primary completion
Nov 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Gabriel STEG
Contact
gabriel.steg@aphp.fr
01 40 25 86 68
Ziad MALLAT
Contact
ziad.mallat@inserm.fr
01 53 98 80 06
Gabriel STEG
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion